Agitation and hyperarousal are among the most distressing symptoms of Alzheimer’s disease—impacting patients, caregivers, and overall quality of life.

Until recently, treatment options were limited and often relied on off-label use of antipsychotics, which carry significant risks in older adults.

Now, a novel approach is emerging: Auvelity (dextromethorphan–bupropion) is gaining attention—and has received recent FDA approval for agitation in Alzheimer’s disease—marking a major shift in treatment strategy.

Glucagon-like peptide-1 (GLP-1) receptor agonists—like semaglutide and liraglutide—are widely known for treating type 2 diabetes and obesity.

But emerging research is shifting the conversation. These medications may also modulate reward pathways in the brain, offering a novel, biologically grounded approach to addiction, compulsive behaviors, and psychiatric symptoms.

For patients in Reno, Nevada, this represents a potential paradigm shift in how we approach treatment-resistant patterns like binge eating, alcohol use, and even certain behavioral addictions.

Low libido, feeling disconnected, mood swings, Reno, NV

Brain fog, sleep disruption, chronic stress Reno, NV